- Skyhawk Therapeutics has received regulatory approvals in the US (IND) and Canada & the UK (CTA acceptances) to initiate its pivotal Phase 2/3 FALCON-HD (004-ANZ and 004-WW) trial evaluating SKY-0515 for Huntington’s disease.
- The oral investigational RNA splicing modifier, developed using Skyhawk’s Skystar platform, is designed to reduce both mutant huntingtin (mHTT) and PMS1 proteins. SKY-0515 has shown strong CNS exposure, a favorable safety profile, and encouraging biomarker and cUHDRS results in earlier studies.
- The global pivotal study will begin enrolling patients across the US, Canada, and the UK. Skyhawk noted that clinician and patient assessments after 12 months of treatment support the therapy’s potential to offer a convenient once-daily oral disease-modifying option for Huntington’s disease.
- Huntington’s disease is a rare, inherited, progressive neurodegenerative disorder with no approved therapies proven to slow disease progression. Skyhawk also plans to advance additional Skystar-derived therapies for rare neurological diseases into clinical development by the end of 2027.
Takeaways
Skyhawk’s global Phase 2/3 FALCON-HD program for SKY-0515 positions the company as a front-runner in disease‑modifying treatment for Huntington’s disease, and if successful, a once‑daily oral RNA splicing modifier that lowers mHTT and PMS1 with favorable safety and cUHDRS data could redefine the standard of care, expand the rare neuro pipeline off the Skystar platform, and materially increase the strategic and commercial value of RNA-targeted small molecules in neurology.
Source: CA Newswire
